Abstract |
We report the efficacy and safety of intravenous low-dose alemtuzumab (10 mg three times weekly for 10 weeks) in 12 patients with relapsed or refractory chronic lymphocytic leukemia. Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression.
|
Authors | Luca Laurenti, Paola Piccioni, Michela Tarnani, Dimitar G Efremov, Alessia Fiorini, Mariagrazia Garzia, Simona Sica |
Journal | Haematologica
(Haematologica)
Vol. 90
Issue 8
Pg. 1143-5
(Aug 2005)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 16079121
(Publication Type: Letter)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
- Antineoplastic Agents
- Alemtuzumab
|
Topics |
- Aged
- Alemtuzumab
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(drug therapy)
- Lymphocyte Count
- Male
- Middle Aged
- Treatment Outcome
|